Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitors

Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitors Descriptor: 6-{8-[(1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydroisoquinolin-2(1H)-yl}-3-{1-[(pyridin-4-yl)methyl]-1H-pyrazol-4-yl}pyridine-2-carboxylic acid, Bcl-2-like protein 1 Authors: Judge, R.A, Judd, A.S. Deposit date: 2020-02-19 Release date: 2020-10-21 Last modified: 2023-10-11 Method: X-RAY DIFFRACTION (1.604 Å) Cite: Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X L Inhibitor. Acs Med.Chem.Lett., 11, 2020与四氢异喹啉-吡啶类抑制剂结合的Bcl-xL晶体结构 配体描述：6-{8-[(1,3-苯并噻唑-2-基)氨基甲酰基]-3,4-二氢异喹啉-2(1H)-基}-3-{1-[(吡啶-4-基)甲基]-1H-吡唑-4-基}吡啶-2-甲酸，Bcl-2样蛋白1 作者：Judge, R.A.、Judd, A.S. 存档日期：2020-02-19 发布日期：2020-10-21 最后修改日期：2023-10-11 检测方法：X射线衍射（X-RAY DIFFRACTION），分辨率1.604埃 引用文献：《A-1331852的发现：首款同类首创、强效且口服生物可利用的BCL-XL抑制剂》，《ACS药物化学快报》，2020年，第11卷